Topcon Healthcare Acquires RetInSight to Accelerate AI-Powered Imaging Innovation in Eye Care
Topcon Healthcare, Inc., a leading provider of medical devices and digital healthcare solutions, today announced the acquisition of RetInSight GmbH, a privately held company based in Vienna, Austria, renowned for its innovation in retinal imaging AI solutions. The move advances Topcon Healthcare’s vision of Healthcare from the Eye™, enhancing access to intelligent diagnostics that increase access to high-quality eye care, reduce healthcare costs, and improve clinical outcomes.
RetInSight’s AI algorithms analyze optical coherence tomography (OCT) images captured in routine clinical care to detect and monitor major retinal diseases – geographic atrophy, neovascular age-related macular degeneration, diabetic macular edema, and retinal vein occlusion – which are the leading causes of vision loss globally. These tools enable earlier intervention and personalized treatment planning, especially for aging populations.
“With Topcon Healthcare’s infrastructure, we can scale reliable and affordable AI software globally," said Prof. Hans Peter Schwarz, Chairman of the Board of RetInSight. "This partnership supports clinical care, drug discovery, and therapeutic innovation worldwide."
RetInSight’s platform, born from pioneering research at the Medical University of Vienna, Department of Ophthalmology and Optometry, under the direction of Prof. Dr. Ursula Schmidt-Erfurth, is already commercialized throughout Europe and is vendor-inclusive supporting interoperability across multiple OCT systems.
“RetInSight’s OCT-based AI expertise will help our global network of partners rapidly deploy innovations,” said Ali Tafreshi, CEO & President of Topcon Healthcare, Inc. “Integrated with our Harmony® vendor-inclusive digital information system, we’re delivering clinical decision support and a scalable ecosystem for AI deployment.”
Already used in pharmaceutical trials, RetInSight’s algorithms also support AI-powered drug development and regulatory pathways, including advancing FDA clearances for U.S. indications.
“Together, we’re enabling seamless patient monitoring across the eye care continuum,” said Dr. Amir Sadeghipour, Managing Director of RetInSight. “This collaboration brings intelligent care to patients anywhere.”
This acquisition marks a pivotal step toward global AI adoption in eye care, fostering a connected, developer-friendly ecosystem that drives better outcomes worldwide.
CONTACTS
Topcon Healthcare
Leslie Amodei
VP, Marketing for Americas
lamodei@topcon.com
RetInSight GmbH
Klaudia Schuh
Head of Marketing & Communications
klaudia.schuh@retinsight.com